Stucki F, Arnet B, Baumgartner C, Beck D, Berchtold W, Bertrand A M, Bleher E A, Caflisch U, Delaleu B, Feldges A
Institute for Clinical and Experimental Cancer Research, University of Berne, Switzerland.
Helv Paediatr Acta. 1988 Nov;43(3):187-93.
The incidence of isolated CNS-relapse in the SPOG ALL studies 1976-1986 was analyzed and the prophylaxis of meningosis leucaemica of the different studies was compared. In the SPOG ALL high-risk study 1979-1983, the incidence of isolated CNS-relapse was significantly higher (17/71, 24%) than in the other studies. In this period, radiotherapy was omitted and the prophylactic treatment consisted only of moderately high doses of intravenous methotrexate and intrathecal methotrexate. In other studies, it was shown that the prophylactic combination of CNS-radiotherapy and intrathecal methotrexate, or the periodic administration of combined intrathecal chemotherapy alone, during the whole therapy of 2 1/2 years, produced comparably good results. The prophylaxis with the combined intrathecal chemotherapy was less neurotoxic and allowed the use of a curative radiotherapy in case of a CNS-relapse.
分析了1976 - 1986年SPOG ALL研究中孤立性中枢神经系统复发的发生率,并比较了不同研究中白血病脑膜炎的预防措施。在1979 - 1983年的SPOG ALL高危研究中,孤立性中枢神经系统复发的发生率显著高于其他研究(17/71,24%)。在此期间,省略了放疗,预防性治疗仅包括中等高剂量的静脉注射甲氨蝶呤和鞘内注射甲氨蝶呤。在其他研究中表明,在整个2.5年的治疗期间,中枢神经系统放疗与鞘内注射甲氨蝶呤的联合预防,或单独定期给予鞘内联合化疗,都产生了相当好的效果。鞘内联合化疗的预防措施神经毒性较小,并且在发生中枢神经系统复发时允许使用根治性放疗。